GDXJ vs XBI
VanEck Junior Gold Miners ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.70%).
Side-by-side metrics
| Metric | GDXJ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.70% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $7.08B | $10.73B |
YTD return | -15.98% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.96 | 1.10 |
P/E ratio | 13.37 | — |
Last price | $99.00 | $164.28 |
Inception | — | — |
Issuer | VanEck | State Street |
GDXJ top holdings
| EVN.AX | Evolution Mining Ltd | 6.49% |
| AGI.TO | Alamos Gold Inc Class A | 6.26% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.24% |
| EDV.L | Endeavour Mining PLC | 5.34% |
| CDE | Coeur Mining Inc | 5.10% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.91% |
| AG.TO | First Majestic Silver Corp | 2.67% |
| IMG.TO | Iamgold Corp | 2.61% |
| HL | Hecla Mining Co | 2.60% |
| ELD.TO | Eldorado Gold Corp | 2.47% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $7.1B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.70%. Its largest holding is Evolution Mining Ltd (EVN.AX), which represents 6.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.